Full-Time

Senior Director

Clinical Sciences

Posted on 8/21/2026

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals

201-500 employees

Develops FDA-approved ophthalmic therapies

Compensation Overview

$255k - $357k/yr

+ Bonus + Stock equity

Irvine, CA, USA

Hybrid

Hybrid work environment with remote work available; up to 30% travel may be required.

PharmD, PhD, MD

Category
Biology & Biotech (1)
Required Skills
Biostatistics

Get referred to Tarsus Pharmaceuticals

See people who can refer or advise you

Requirements
  • Provide an advanced degree in sciences, such as a PharmD, MD, or PhD, with deep experience in early clinical development.
  • Have a minimum of 10 years of biotechnology or pharmaceutical clinical development experience.
  • Have a minimum of 8 years of leadership in clinical trial management experience.
  • Demonstrate an established leadership track record with performance-based people management experience, problem solving, collaboration, cross-functional leadership, and effective communication skills.
  • Have expertise with standard operating procedures, Good Clinical Practice, and regulatory and compliance guidelines for clinical trials.
  • Be willing to work hands-on and delve into details.
Responsibilities
  • Lead the Clinical Science (Eyecare) function and own the scientific integrity, quality, and strategic impact of eyecare clinical studies from early development through late-stage registration and lifecycle management.
  • Partner with Clinical Operations, Regulatory, Biostatistics, Medical Affairs, and Commercial to translate target product profiles into clinical development plans and high-quality trial designs.
  • Provide scientific leadership to cross-functional study and program teams, ensuring timely study start-up, enrollment, database lock, analysis, and readouts.
  • Lead the design of clinical development plans and individual study protocols, including objectives, endpoints, inclusion and exclusion criteria, assessments, and statistical assumptions.
  • Own clinical deliverables and contribute to protocol development, document authoring, data review, study-level problem solving, and execution decisions.
  • Shape clinical plans, including timelines, budgets, and oversight of clinical teams.
  • Build and maintain relationships with investigators, key opinion leaders, and external partners; contribute to publication strategy and scientific communications.
  • Drive innovation in clinical endpoints, biomarkers, and digital tools, and improve clinical science processes, templates, and data review frameworks.
  • Author and critically review clinical and regulatory documents, including protocols, statistical analysis plans, clinical study reports, investigator brochures, and clinical value dossiers.
  • Conduct research to develop foundational educational material for early development program strategies.
  • Interpret clinical data and support data-driven decisions.
  • Serve as program lead on early development core teams, investigator meetings, and scientific advisory boards.
  • Engage with internal and external stakeholders, including key opinion leaders and regulators.
  • Foster leadership competencies, including empowerment, emotional intelligence, capacity building, business acumen, and innovation.
  • Collaborate with Clinical Operations, Regulatory Affairs, Translational Sciences, Biostatistics, Medical Affairs, and other functions to ensure robust trial design, scientific and operational alignment, and execution.
  • Report directly to the Senior Vice President of Development.
Desired Qualifications
  • Experience in ophthalmology is preferred.
  • Experience in dermatology or infectious diseases is a plus.
Tarsus Pharmaceuticals

Tarsus Pharmaceuticals

View

Tarsus Pharmaceuticals develops and markets treatments for eye care and infectious diseases, including XDEMVY, an FDA-approved lotilaner eye drop for Demodex Blepharitis. It works by applying the ophthalmic solution to the eyelids to kill Demodex mites and reduce eyelid inflammation. The company differentiates itself with a focused ocular and infectious diseases portfolio and by pursuing collaborations to advance its pipeline alongside selling approved products. Its goal is to address unmet medical needs, grow its product lineup, and expand into additional indications in eye care and infectious diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

Irvine, California

Founded

2017

Get referred to Tarsus Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 XDEMVY sales hit $173.9 million, up 69%, lifting guidance to $705 million.
  • Cash reached $449.7 million on June 30, 2026, funding Alkeus integration and trials.
  • Alkeus adds Phase 3 Stargardt disease, expanding Tarsus beyond XDEMVY dependence.

What critics are saying

  • Culper Research accused Tarsus on July 1, 2026 of an illegal Medicare copay scheme.
  • Glaukos entered Demodex blepharitis in June 2026, threatening XDEMVY pricing and share gains.
  • Any DOJ action on XDEMVY copay practices can cripple Tarsus's only revenue engine.

What makes Tarsus Pharmaceuticals unique

  • XDEMVY remains the only FDA-approved treatment for Demodex blepharitis, preserving first-mover advantage.
  • Tarsus now combines commercial ophthalmology with late-stage retina assets from iRenix and Alkeus.
  • Its lotilaner platform already delivered a $15 million China milestone on March 23, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

3%
Yahoo Finance
Aug 7th, 2026
Tarsus raises 2026 XDEMVY sales outlook to $705M, acquires Alkeus for $450M upfront

Tarsus Pharmaceuticals reported strong Q2 performance for its Demodex blepharitis treatment XDEMVY, with sales rising 69% year-over-year to $173.9 million. The company raised its 2026 sales guidance to $685–$705 million, noting that over 700,000 patients have used the treatment since launch. Tarsus announced plans to acquire Alkeus Pharmaceuticals for $450 million upfront, adding late-stage Stargardt disease therapy ALK-001 to its pipeline. The Phase III NORTHSTAR trial is underway, with top-line results expected in the second half of 2029. The acquisition will expand Tarsus' strategy beyond XDEMVY into retina care. However, the company raised 2026 R&D guidance to $190–$210 million due to increased near-term spending. Profitability could potentially arrive in 2027, subject to acquisition-related costs.

Vision Monday
Aug 7th, 2026
Tarsus to acquire Alkeus in $450 million deal, reports strong Quarter and half.

Tarsus to acquire Alkeus in $450 million deal, reports strong Quarter and half. Friday, August 7, 2026 12:24 AM IRVINE, Calif. - Tarsus Pharmaceuticals announced yesterday that it has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc., a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease. The deal includes an upfront consideration of about $450 million, the companies said, comprising $270 million in cash and $180 million in Tarsus common stock. The pending transaction is expected to close this year, and also includes a milestone of up to $350 million upon potential regulatory approval and first commercial sale. The news was announced along with a strong unaudited financial report that saw total Q2 revenue for Tarsus rise to $173.9 million and first half revenue rise to nearly $336 million. According to the announcement, the planned acquisition of Alkeus represents what Tarsus said is an important step in its long-term strategy to build a leading eyecare company by bringing differentiated medicines to patients with significant unmet needs. The acquisition is expected to expand Tarsus' growing presence in retina, complement the capabilities established through the acquisition of iRenix Medical last month, and add a differentiated phase 3 program potentially addressing Stargardt disease. "From the beginning, our strategy has been to build a leading eyecare company by identifying significant diseases where patients have been starving for innovation and bringing forward medicines with the potential to change the standard of care," said Bobby Azamian, MD, Ph.D., CEO and chairman of Tarsus. "We believe gildeuretinol has the potential to be a transformational medicine for Stargardt disease and complements the retina capabilities we are already building through IRX-101. We also have tremendous respect for the Alkeus team and the exceptional work they have done to identify and bring forward an optimal asset to potentially address this blinding disease." Second Quarter and First Half Reporting The acquisition announcement came nearly concurrent with strong unaudited second quarter and first half reporting from Tarsus. Net sales of $173.9 million marked more than 69 percent growth versus last year's Q2 of $102.7 million, with net product sales of XDEMVY (lotilaner ophthalmic solution) 0.25%, a prescription eye drop designed to treat Demodex blepharitis, serving as a primary revenue driver, as well as what the company said was higher volume and improvements in the gross-to-net discount. Total first-half revenue for the company was reported at nearly $336 million (versus $181 million for the same period last year), with $319.3 million attributed to XDEMVY product sales and $16.7 million attributed to license fees and collaborations. Cost of sales in Q2 were $12.1 million compared with $6.2 million for the same period in 2025, due to manufacturing costs related to Xdemvy, the company said. Research and development expenses totaled $31.0 million compared with $15.6 million for the same period in 2025. Selling, general and administrative expenses were $150.7 million compared with $103.0 million for the same period in 2025. Net loss in the second quarter narrowed to $18.6 million, compared with $20.3 million for the same period in 2025, the company said. As of June 30, 2026, cash, cash equivalents and marketable securities were $449.7 million. The company also took the further step of increasing 2026 net sales guidance for XDEMVY to $685 million to $705 million. Related to the pending acquisition, Barclays is acting as exclusive financial advisor to Tarsus and Jefferies is acting as exclusive financial advisor to Alkeus. Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP is acting as legal counsel to Tarsus, and Latham & Watkins LLP is acting as legal counsel to Alkeus.

Central Charts
Aug 6th, 2026
Tarsus Pharmaceuticals raises $125M in oversubscribed PIPE financing to fund Alkeus acquisition

Tarsus Pharmaceuticals has secured $125 million through an oversubscribed private placement equity financing. The transaction includes participation from investors in Alkeus Pharmaceuticals, which Tarsus announced it would acquire earlier the same day. Notable investors include TCGX, Bain Capital Life Sciences, Wellington Management, ADAR1 Capital Management, Sirenia Capital Management LP, RTW Investments, and Vestal Point Capital. The company is selling 2,098,519 shares of common stock at $56 per share and pre-funded warrants to purchase 133,625 additional shares. The financing is expected to close on 7 August 2026. Tarsus intends to use the proceeds to fund clinical development, commercial activities, and general corporate purposes. Barclays is serving as lead placement agent, with BofA Securities and William Blair as co-placement agents.

GlobeNewswire
Aug 6th, 2026
Tarsus Pharmaceuticals acquires Alkeus for $450M to advance Stargardt disease treatment

Tarsus Pharmaceuticals has agreed to acquire Alkeus Pharmaceuticals for approximately $450 million upfront, consisting of $270 million in cash and $180 million in Tarsus stock. The deal includes potential milestone payments of up to $350 million upon regulatory approval and first commercial sale, plus low single-digit royalties. The acquisition adds gildeuretinol (ALK-001), a Phase 3 oral investigational medicine for Stargardt disease, an inherited retinal condition affecting over 36,000 people in the US with no FDA-approved treatments. More than 400 individuals have been treated with the drug to date, showing encouraging clinical findings. Top-line Phase 3 NORTHSTAR data are expected in the second half of 2029. The transaction has been approved by both companies' boards and Alkeus stockholders. It is expected to close in 2026, subject to regulatory clearances and customary conditions.

Minichart
Jul 9th, 2026
Tarsus Pharmaceuticals Acquires iRenix Medical to Advance Eye Care with Late-Stage IRX-101 Asset

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has announced a major strategic acquisition, taking over privately held iRenix Medical, Inc., a clinical-stage ophthalmic biopharmaceutical company. This transaction marks a significant step in Tarsus’ ambition to expand its leadership in the eye care market and could have material implications for the company’s future growth, pipeline development, and share price.